Literature DB >> 22510383

Secondary treatment of acute graft-versus-host disease: a critical review.

Paul J Martin1, Yoshihiro Inamoto, Mary E D Flowers, Paul A Carpenter.   

Abstract

Management of steroid-resistant or steroid-refractory acute graft-versus-host disease (aGVHD) poses one of the most vexing and difficult problems faced by transplantation physicians. In the current study, we used 10 criteria to evaluate 67 reports describing secondary treatment of patients with aGVHD. The goal of this exercise was not only to provide a critical summary of the literature but also to offer suggestions that could improve future studies. Areas especially in need of improvement include the use of a consistent treatment regimen, the assessment of response at a consistent prespecified time point, consideration of concomitant treatment in assessing response, documentation that selection bias was minimized, and the use of methods that test a formal statistical hypothesis based on a contemporaneous or historical benchmark. Our results suggest that previous published reports collectively offer little guidance in discerning the most effective treatments for patients with steroid-resistant or steroid-refractory aGVHD. Adherence to the proposed criteria in future reports would enable meaningful comparisons across studies and thereby accelerate progress in evaluating new treatments for patients with aGVHD.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22510383      PMCID: PMC3386268          DOI: 10.1016/j.bbmt.2012.04.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  74 in total

1.  A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease.

Authors:  Chie Onishi; Kazuteru Ohashi; Takeshi Sawada; Mikako Nakano; Takeshi Kobayashi; Takuya Yamashita; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

2.  Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.

Authors:  V A M Funke; C R de Medeiros; D C Setúbal; J Ruiz; M A Bitencourt; C M Bonfim; J Z Neto; R Pasquini
Journal:  Bone Marrow Transplant       Date:  2006-05       Impact factor: 5.483

3.  Infliximab treatment for steroid-refractory acute graft-versus-host disease.

Authors:  Francesca Patriarca; Alessandra Sperotto; Daniela Damiani; Giuseppe Morreale; Francesca Bonifazi; Attilio Olivieri; Fabio Ciceri; Giuseppe Milone; Simone Cesaro; Giuseppe Bandini; Giorgio Dini; Paolo Corradini; Renato Fanin
Journal:  Haematologica       Date:  2004-11       Impact factor: 9.941

Review 4.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

5.  Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.

Authors:  M Miano; D Cuzzubbo; P Terranova; S Giardino; E Lanino; G Morreale; E Castagnola; G Dini; M Faraci
Journal:  Bone Marrow Transplant       Date:  2008-10-13       Impact factor: 5.483

Review 6.  Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement.

Authors:  Paul J Martin; Carlos R Bachier; Hans-Georg Klingemann; Philip L McCarthy; Paul Szabolcs; Joseph P Uberti; Michael W Schuster; Daniel Weisdorf; Nelson J Chao; Partow Kebriaei; Elizabeth J Shpall; Margaret L Macmillan; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2009-05-13       Impact factor: 5.742

7.  Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report.

Authors:  Massimo Berger; Berger Massimo; Rosanna Pessolano; Pessolano Rosanna; Roberto Albiani; Albiani Roberto; Sebastian Asaftei; Asaftei Sebastian; Veronica Barat; Barat Veronica; Francesca Carraro; Carraro Francesca; Eleonara Biasin; Biasin Eleonora; Enrico Madon; Madon Enrico; Franca Fagioli; Fagioli Franca
Journal:  J Pediatr Hematol Oncol       Date:  2007-10       Impact factor: 1.289

8.  Extracorporeal photochemotherapy may improve outcome in children with acute GVHD.

Authors:  E Calore; A Calò; G Tridello; S Cesaro; M Pillon; S Varotto; M V Gazzola; R Destro; P Marson; L Trentin; M Carli; C Messina
Journal:  Bone Marrow Transplant       Date:  2008-06-23       Impact factor: 5.483

9.  Rapamycin for refractory acute graft-versus-host disease.

Authors:  David Ghez; Marie Thérèse Rubio; Natacha Maillard; Felipe Suarez; Marie-Olivia Chandesris; Richard Delarue; Bénédicte Deau-Fischer; Bruno Varet; Olivier Hermine; Agnès Buzyn
Journal:  Transplantation       Date:  2009-11-15       Impact factor: 4.939

10.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome.

Authors:  D Weisdorf; R Haake; B Blazar; W Miller; P McGlave; N Ramsay; J Kersey; A Filipovich
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

View more
  25 in total

Review 1.  Immunopathology and biology-based treatment of steroid-refractory graft-versus-host disease.

Authors:  Tomomi Toubai; John Magenau
Journal:  Blood       Date:  2020-07-23       Impact factor: 22.113

2.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

3.  Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice.

Authors:  T Ruutu; A Gratwohl; T de Witte; B Afanasyev; J Apperley; A Bacigalupo; F Dazzi; P Dreger; R Duarte; J Finke; L Garderet; H Greinix; E Holler; N Kröger; A Lawitschka; M Mohty; A Nagler; J Passweg; O Ringdén; G Socié; J Sierra; A Sureda; W Wiktor-Jedrzejczak; A Madrigal; D Niederwieser
Journal:  Bone Marrow Transplant       Date:  2013-07-29       Impact factor: 5.483

4.  Extracorporeal photopheresis in the management of graft-versus-host disease.

Authors:  C Bredeson; R B Rumble; N P Varela; J Kuruvilla; C T Kouroukis
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

5.  The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD.

Authors:  M Nadeau; S Perreault; S Seropian; F Foss; I Isufi; D L Cooper
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

6.  Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure.

Authors:  Emma Das-Gupta; Hildegard Greinix; Ryan Jacobs; Li Zhou; Bipin N Savani; Brian G Engelhardt; Adetola Kassim; Nina Worel; Robert Knobler; Nigel Russell; Madan Jagasia
Journal:  Haematologica       Date:  2014-08-22       Impact factor: 9.941

7.  Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.

Authors:  I García-Cadenas; I Rivera; R Martino; A Esquirol; P Barba; S Novelli; G Orti; J Briones; S Brunet; D Valcarcel; J Sierra
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

8.  Compassionate use of cell products.

Authors:  Gil Cunha de Santis; Eugênia Maria Amorim Ubiali; Dimas Tadeu Covas
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 9.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

Authors:  Paul J Martin; J Douglas Rizzo; John R Wingard; Karen Ballen; Peter T Curtin; Corey Cutler; Mark R Litzow; Yago Nieto; Bipin N Savani; Jeffrey R Schriber; Paul J Shaughnessy; Donna A Wall; Paul A Carpenter
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-14       Impact factor: 5.742

10.  International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

Authors:  Andrew C Harris; Rachel Young; Steven Devine; William J Hogan; Francis Ayuk; Udomsak Bunworasate; Chantiya Chanswangphuwana; Yvonne A Efebera; Ernst Holler; Mark Litzow; Rainer Ordemann; Muna Qayed; Anne S Renteria; Ran Reshef; Matthias Wölfl; Yi-Bin Chen; Steven Goldstein; Madan Jagasia; Franco Locatelli; Stephan Mielke; David Porter; Tal Schechter; Zhanna Shekhovtsova; James L M Ferrara; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-16       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.